Randomized, Non-comparative Neoadjuvant Phase II Study in patients with ER+/HER2- Breast Cancer >= 2cm with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole
- White, Michelle (Primary Chief Investigator (PCI))
Project: Research